Pharmaceutical composition containing stabilized nucleic acid adjuvant
AssigneeSml Biopharm Co., Ltd.
InventorsJae Hwan Nam, Gyo Chang Keum, Hyo Jung Park, Eun Kyoung Bang, Hae Li Ko
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.
Claims18
A pharmaceutical composition including:
- a nucleic acid molecule of an adjuvant;
- and
- a metal complex stabilizing the nucleic acid molecule and having the following structure of Formula 1 or a pharmaceutically acceptable salt thereof:
- wherein each of L1 and L2 is independently a C1-C20 aliphatic bridging group;
- each of m and n is independently 0 or 1;
- R is a C1-C20 alkyl group or
- wherein asterisk indicate a linking site,
- wherein the nucleic acid molecule includes at least one IRES (Internal ribosome entry site) element of an expression control sequence, and
- wherein the nucleic acid molecule further includes multiple thymidines inserted to an upstream of the at least one IRES element, wherein the multiple thymidines include 20 to 400 thymidines.
A composition for stabilizing a nucleic acid molecule of an adjuvant, the composition including a metal complex having the following structure of Formula 1 or a pharmaceutically acceptable salt thereof:
- wherein each of L1 and L2 is independently a C1-C20 aliphatic bridging group;
- each of m and n is independently 0 or 1;
- R is a C1-C20 alkyl group or
- wherein asterisk indicate a linking site,
- wherein the nucleic acid molecule includes at least one IRES (Internal ribosome entry site) element of an expression control sequence, and
- wherein the nucleic acid molecule further includes multiple thymidines inserted to an upstream of the at least one IRES element, wherein the multiple thymidines include 20 to 400 thymidines.
Dependencies are inferred from the claim text.